SG10201502490YA - Norovirus vaccine formulations - Google Patents

Norovirus vaccine formulations

Info

Publication number
SG10201502490YA
SG10201502490YA SG10201502490YA SG10201502490YA SG10201502490YA SG 10201502490Y A SG10201502490Y A SG 10201502490YA SG 10201502490Y A SG10201502490Y A SG 10201502490YA SG 10201502490Y A SG10201502490Y A SG 10201502490YA SG 10201502490Y A SG10201502490Y A SG 10201502490YA
Authority
SG
Singapore
Prior art keywords
vaccine formulations
norovirus vaccine
norovirus
formulations
vaccine
Prior art date
Application number
SG10201502490YA
Other languages
English (en)
Inventor
Charles Richardson
Thomas S Vedvick
Thomas R Foubert
William T Tino
Original Assignee
Ligocyte Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39268804&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201502490Y(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ligocyte Pharmaceuticals Inc filed Critical Ligocyte Pharmaceuticals Inc
Publication of SG10201502490YA publication Critical patent/SG10201502490YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
SG10201502490YA 2006-09-29 2007-09-28 Norovirus vaccine formulations SG10201502490YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84791206P 2006-09-29 2006-09-29
US97339207P 2007-09-18 2007-09-18

Publications (1)

Publication Number Publication Date
SG10201502490YA true SG10201502490YA (en) 2015-05-28

Family

ID=39268804

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201502490YA SG10201502490YA (en) 2006-09-29 2007-09-28 Norovirus vaccine formulations
SG2011071123A SG174845A1 (en) 2006-09-29 2007-09-28 Norovirus vaccine formulations
SG10202012986SA SG10202012986SA (en) 2006-09-29 2007-09-28 Norovirus vaccine formulations

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG2011071123A SG174845A1 (en) 2006-09-29 2007-09-28 Norovirus vaccine formulations
SG10202012986SA SG10202012986SA (en) 2006-09-29 2007-09-28 Norovirus vaccine formulations

Country Status (17)

Country Link
US (8) US7955603B2 (es)
EP (4) EP2066354B1 (es)
JP (3) JP5476544B2 (es)
KR (1) KR101515489B1 (es)
AU (1) AU2007303608B2 (es)
CA (1) CA2664157C (es)
CY (1) CY1118492T1 (es)
DK (3) DK2601969T3 (es)
ES (3) ES2577833T3 (es)
HK (1) HK1184057A1 (es)
HU (2) HUE032422T2 (es)
LT (1) LT2601970T (es)
PL (2) PL2601970T3 (es)
PT (1) PT2601970T (es)
SG (3) SG10201502490YA (es)
SI (1) SI2601970T1 (es)
WO (1) WO2008042789A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2601970T3 (pl) * 2006-09-29 2017-07-31 Takeda Vaccines, Inc. Preparaty szczepionki przeciw norowirusowi
US8481693B2 (en) 2007-03-14 2013-07-09 Takeda Vaccines (Montana), Inc. Virus like particle purification
EP2190471A4 (en) * 2007-09-18 2012-05-09 Ligocyte Pharmaceuticals Inc METHOD FOR TRANSFERRING A PROTECTIVE REACTION ON NOROVIRES
US20100266636A1 (en) * 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
NO2324113T3 (es) * 2008-08-08 2018-07-28
US20120121710A1 (en) * 2009-03-27 2012-05-17 Arizona Board Of Regents For And On Behalf Of Arizona State University Mucosal Immunization
US20110070260A1 (en) * 2009-09-09 2011-03-24 Baric Ralph S Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use
WO2011079260A2 (en) * 2009-12-23 2011-06-30 Arizona Board Of Regents Acting For And On Behalf Of Arizona State University Stabilized virus like particles having enhanced mucosal immunogenicity
EP2525816A4 (en) * 2010-01-21 2013-10-02 Ligocyte Pharmaceuticals Inc PRESENTATION OF TARGETED HETEROLOGOUS ANTIGENS ON CALICIVIRUS VIRAL PSEUDO PARTICLES
ES2874817T3 (es) * 2010-04-15 2021-11-05 Shin Nippon Biomedical Laboratories Ltd Procedimiento para generar una formulación de vacuna en polvo seco para suministro intranasal
AU2012244074B2 (en) * 2010-04-15 2015-01-15 Km Biologics Co., Ltd. Methods and compositions for intranasal delivery
ES2656527T3 (es) * 2011-07-11 2018-02-27 Takeda Vaccines, Inc. Formulaciones parenterales de vacunas de norovirus
JOP20130186B1 (ar) * 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
US20140017257A1 (en) * 2012-07-11 2014-01-16 Xi Jiang IgY From Norovirus P Particles And Their Derivatives
HUE038527T2 (hu) * 2012-12-28 2018-10-29 Cellestis Ltd Sejtek által közvetített immunválasz
US9975923B2 (en) 2013-03-15 2018-05-22 The University Of North Carolina At Chapel Hill Methods and compositions for norovirus blockade epitopes
EP2970395A4 (en) * 2013-03-15 2017-03-29 The University of North Carolina At Chapel Hill Methods and compositions for norovirus blockade epitopes
JP2015017065A (ja) * 2013-07-12 2015-01-29 株式会社Ｕｍｎファーマ ノロウイルスのウイルス様粒子を含む医薬組成物
JP2015015931A (ja) 2013-07-12 2015-01-29 株式会社Ｕｍｎファーマ ウイルス様粒子を含む培養物の製造方法
JP6479305B2 (ja) 2013-07-12 2019-03-06 株式会社Ｕｍｎファーマ ウイルス様粒子の精製方法
US9937258B2 (en) 2013-07-17 2018-04-10 Dow Global Technologies Llc Composition for application to a nasal mucosa comprising a methylcellulose
KR102474663B1 (ko) 2013-10-03 2022-12-07 다케다 백신즈 인코포레이티드 세포주로부터 랍도바이러스를 탐지 및 제거하는 방법
WO2015093452A1 (ja) 2013-12-16 2015-06-25 武田薬品工業株式会社 マイクロニードル
EP3341019A4 (en) * 2015-08-28 2019-07-31 Ology Bioservices, Inc. VACCINE AGAINST A NOROVIRUS
KR101915740B1 (ko) * 2016-03-18 2018-11-06 (주)인테라 목적 단백질의 발현 효율을 증진시키기 위한 신규한 펩타이드 및 이를 포함하는 융합 단백질
CN107184970A (zh) * 2017-02-16 2017-09-22 北京生物制品研究所有限责任公司 口服诺如病毒亚单位疫苗及lt作为该疫苗佐剂的用途
EP3600397A4 (en) 2017-03-28 2021-01-27 Children's Hospital Medical Center NOROVIRUS PARTICLE VACCINES AND THEIR MANUFACTURING AND USE PROCEDURES
MX2020005530A (es) 2017-11-30 2021-01-15 Medicago Inc Proteinas vp1 de norovirus modificadas y psv que comprenden proteinas vp1 de norovirus modificadas.
EP3752185A1 (en) 2018-02-15 2020-12-23 Icon Genetics GmbH Immunogenic composition and vaccine for generating an immune response to norovirus
JP6713013B2 (ja) * 2018-03-06 2020-06-24 株式会社イーダブルニュートリション・ジャパン 貝類のノロウイルス不活化方法
CA3106471A1 (en) 2018-07-13 2020-01-16 Medicago Inc. Modified norovirus vp1 proteins and vlps comprising modified norovirus vp1 proteins
WO2020041192A1 (en) 2018-08-20 2020-02-27 Takeda Vaccines, Inc. Vlp formulations
CN113348000A (zh) * 2018-09-17 2021-09-03 德克萨斯大学体系董事会 用于治疗骨损伤的组合物和方法
US11523988B2 (en) * 2018-11-29 2022-12-13 Catalent U.K. Swindon Zydis Limited Oral dispersible vaccine comprising virosomes
EP3698773A1 (en) 2019-02-21 2020-08-26 Università degli Studi di Parma Composition and manufacturing of powders containing nanoadjuvants for mucosal vaccination
WO2020182860A1 (en) 2019-03-12 2020-09-17 Icon Genetics Gmbh Norovirus-like particles with improved stability
CN115023219A (zh) * 2019-08-13 2022-09-06 艾尔特免疫公司 治疗剂的有效性及其施用途径
WO2022246323A1 (en) 2021-05-21 2022-11-24 Takeda Vaccines, Inc. Solid composition, freeze-drying method and glass vial
CN117330750A (zh) * 2023-12-01 2024-01-02 北京生物制品研究所有限责任公司 一种筛选新冠病毒早期毒种的方法和制造疫苗的方法

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6572862B1 (en) 1989-11-08 2003-06-03 Baylor College Of Medicine Methods and reagents to detect and characterize Norwalk and related viruses
AU1893592A (en) * 1991-03-25 1992-10-21 Board Of Trustees Of The Leland Stanford Junior University Norwalk virus human gastroenteritis agent and molecular cloning of corresponding cdnas
WO1993021325A1 (en) 1992-04-08 1993-10-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Wild-type measles virus glycoproteins: vaccine and detection method therefor
EP1175912A1 (en) 1993-03-23 2002-01-30 SmithKline Beecham Biologics SA Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
US5788970A (en) 1994-03-29 1998-08-04 The University Of Maryland College Park Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon
MXPA96005662A (es) 1994-05-16 2004-08-19 Merck & Co Inc Vacunas de papilomavirus.
US5645051A (en) * 1995-04-21 1997-07-08 Dura Pharmaceuticals, Inc. Unit dose dry powder inhaler
US5861241A (en) * 1995-08-16 1999-01-19 University Of Massachusetts Monoclonal antibodies for detecting Norwalk virus
GB9525083D0 (en) * 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
US5834015A (en) 1996-09-11 1998-11-10 Albany Medical College Protein-lipid vesicles and autogenous vaccine comprising the same
US5953727A (en) 1996-10-10 1999-09-14 Incyte Pharmaceuticals, Inc. Project-based full-length biomolecular sequence database
US6491919B2 (en) * 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
CA2286294A1 (en) 1997-04-08 1998-10-15 Merck & Co., Inc. Stabilized human papillomavirus formulations
JP2002508748A (ja) 1997-05-01 2002-03-19 カイロン コーポレイション アジュバントとしてのウイルス様粒子の使用
US20040265377A1 (en) 1997-10-27 2004-12-30 Harry Seager Solid dispersing vaccine composition for oral delivery
AU760633B2 (en) 1998-08-14 2003-05-22 Merck Sharp & Dohme Corp. Process for purifying human papillomavirus virus-like particles
ATE323508T1 (de) 1998-12-17 2006-05-15 Merck & Co Inc Synthetische virus-ähnliche partikel mit heterologen epitopen.
CA2361837C (en) 1999-02-05 2011-06-07 Merck And Co., Inc. Human papilloma virus vaccine formulations
CA2783140C (en) 1999-06-22 2016-07-26 Japan As Represented By Directors-General National Institute Of Infectious Diseases Srsv detection kit
WO2003068163A2 (en) 2002-02-14 2003-08-21 Novavax, Inc. Optimization of gene sequences of chimeric virus-like particles for expression in insect cells
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
EP2591771A1 (en) 2002-04-11 2013-05-15 MedImmune, LLC Preservation of bioactive materials by freeze dried foam
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
CA2486118A1 (en) 2002-06-07 2003-12-18 Large Scale Biology Corporation Flexible vaccine assembly and vaccine delivery platform
JP4598519B2 (ja) 2002-06-20 2010-12-15 サイトス バイオテクノロジー アーゲー アジュバントとして使用するためのパッケージ化されたウィルス様粒子：調製法及び使用法
ATE426412T1 (de) 2003-01-30 2009-04-15 Novartis Vaccines & Diagnostic Adjuvante influenza-vakzine
EP1599188A2 (en) 2003-02-20 2005-11-30 Becton, Dickinson and Company POWDER FORMULATIONS OF RECOMBINANT STAPHYLOCOCCAL, ENTEROTOXIN B (<SB>R</SB>SEB) MADE BY ATMOSPHERIC SPRAY-FREEZE DRYING FOR IMPROVED VACCINATION
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US7879338B2 (en) 2003-07-21 2011-02-01 Boyce Thompson Institute For Plant Research Vectors and methods for immunization against norovirus using transgenic plants
WO2005030806A2 (en) 2003-09-24 2005-04-07 Montana State University Norovirus monoclonal antibodies and peptides
US7795242B2 (en) 2003-10-15 2010-09-14 The Brigham And Women's Hospital, Inc. Methods and compositions for immunomodulation
US20050215501A1 (en) 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
FR2863890B1 (fr) 2003-12-19 2006-03-24 Aventis Pasteur Composition immunostimulante
US7481997B1 (en) * 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
US20050260225A1 (en) 2004-05-18 2005-11-24 Goldberg Joanna B Intranasal recombinant Salmonella vaccine encoding heterologous polysaccharide antigens
CU23496A1 (es) 2004-09-03 2010-02-23 Ct Ingenieria Genetica Biotech Composición vacunal contra el virus de la hepatitis c
AU2005295438B2 (en) 2004-10-20 2012-07-05 Sanofi Pasteur Biologics, Llc Vaccines against Japanese encephalitis virus and West Nile virus
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
CA2593176A1 (en) 2005-01-05 2006-07-13 Peter D. Katsikis Delivery vehicles, bioactive substances and viral vaccines
WO2006086188A2 (en) 2005-01-31 2006-08-17 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
NZ599345A (en) 2005-02-18 2013-07-26 Novartis Vaccines & Diagnostic Immunogens from uropathogenic Escherichia Coli
KR20070112225A (ko) 2005-03-18 2007-11-22 사이토스 바이오테크놀로지 아게 고양이 알레르겐 컨쥬게이트 및 그의 용도
US20070041999A1 (en) 2005-06-01 2007-02-22 Lada Rasochova Production of multivalent virus like particles
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
WO2007081447A2 (en) 2005-11-22 2007-07-19 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
JP2007145775A (ja) 2005-11-29 2007-06-14 Falco Life Science:Kk ノロウイルスｇｉの高感度検出方法
PL2601970T3 (pl) 2006-09-29 2017-07-31 Takeda Vaccines, Inc. Preparaty szczepionki przeciw norowirusowi
PL2121011T3 (pl) 2006-12-06 2014-10-31 Novartis Ag Szczepionki zawierające antygeny czterech szczepów wirusa grypy
US8481693B2 (en) 2007-03-14 2013-07-09 Takeda Vaccines (Montana), Inc. Virus like particle purification
US8474614B2 (en) * 2007-03-14 2013-07-02 BBY Solutions Protective container for a flat screen monitor
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
EP2190471A4 (en) * 2007-09-18 2012-05-09 Ligocyte Pharmaceuticals Inc METHOD FOR TRANSFERRING A PROTECTIVE REACTION ON NOROVIRES
NO2324113T3 (es) 2008-08-08 2018-07-28
EP2381959A1 (en) 2009-01-22 2011-11-02 Pharmathene Inc. Stable vaccine compositions and methods of use
AU2010212547B2 (en) 2009-02-10 2015-03-12 Seqirus UK Limited Influenza vaccine regimens for pandemic-associated strains
US20110070260A1 (en) 2009-09-09 2011-03-24 Baric Ralph S Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use
EP2525816A4 (en) 2010-01-21 2013-10-02 Ligocyte Pharmaceuticals Inc PRESENTATION OF TARGETED HETEROLOGOUS ANTIGENS ON CALICIVIRUS VIRAL PSEUDO PARTICLES
BR112012029912A2 (pt) 2010-05-26 2016-11-16 Selecta Biosciences Inc vácinas de combinação de nanotransportadores sintéticos
ES2656527T3 (es) 2011-07-11 2018-02-27 Takeda Vaccines, Inc. Formulaciones parenterales de vacunas de norovirus
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات

Also Published As

Publication number Publication date
US20120093861A1 (en) 2012-04-19
EP2601969A3 (en) 2013-08-21
EP2066354A4 (en) 2010-10-20
US20130273105A1 (en) 2013-10-17
DK2601969T3 (en) 2016-04-18
US10010599B2 (en) 2018-07-03
KR101515489B1 (ko) 2015-04-30
EP2601969B1 (en) 2016-03-30
ES2618885T3 (es) 2017-06-22
US7955603B2 (en) 2011-06-07
US20120156243A1 (en) 2012-06-21
EP2066354B1 (en) 2013-04-17
AU2007303608B2 (en) 2013-05-02
JP6134364B2 (ja) 2017-05-24
CY1118492T1 (el) 2017-07-12
LT2601970T (lt) 2017-04-25
EP2601970B1 (en) 2016-10-26
DK2601970T3 (en) 2017-02-06
US10512682B2 (en) 2019-12-24
HK1184057A1 (zh) 2014-01-17
EP2641613A1 (en) 2013-09-25
US20080299152A1 (en) 2008-12-04
WO2008042789A1 (en) 2008-04-10
US20160008455A1 (en) 2016-01-14
US9272028B2 (en) 2016-03-01
JP2013234188A (ja) 2013-11-21
PL2601970T3 (pl) 2017-07-31
SG174845A1 (en) 2011-10-28
HUE032422T2 (en) 2017-09-28
JP2010505766A (ja) 2010-02-25
AU2007303608A1 (en) 2008-04-10
KR20090079912A (ko) 2009-07-22
PT2601970T (pt) 2017-02-02
DK2066354T3 (da) 2013-05-27
ES2420136T3 (es) 2013-08-22
SG10202012986SA (en) 2021-01-28
CA2664157C (en) 2015-12-01
JP5476544B2 (ja) 2014-04-23
US20140286994A1 (en) 2014-09-25
US9861691B2 (en) 2018-01-09
JP5898133B2 (ja) 2016-04-06
PL2601969T3 (pl) 2016-10-31
EP2601970A1 (en) 2013-06-12
ES2577833T3 (es) 2016-07-19
CA2664157A1 (en) 2008-04-10
US20130273148A1 (en) 2013-10-17
SI2601970T1 (sl) 2017-04-26
EP2066354A1 (en) 2009-06-10
US20190125853A1 (en) 2019-05-02
EP2601969A2 (en) 2013-06-12
US9308249B2 (en) 2016-04-12
HUE028978T2 (en) 2017-02-28
JP2016020378A (ja) 2016-02-04
US8431116B2 (en) 2013-04-30

Similar Documents

Publication Publication Date Title
HK1184057A1 (zh) 諾如病毒疫苗製劑
GB2435419B (en) Formulations
GB0607088D0 (en) Vaccine
EP2046930A4 (en) FORMULATIONS BASED ON RHAMNOLIPIDS
GB0605780D0 (en) Formulations
ZA200808489B (en) Nicotine-carrier vaccine formulation
GB0718409D0 (en) Formulations
GB0610336D0 (en) Formulations
HK1129836A1 (zh) 疫苗
ZA200901592B (en) Vaccine
GB0718404D0 (en) Formulations
GB0711440D0 (en) Aqueous formulations
GB0625593D0 (en) Vaccine
GB0620336D0 (en) Vaccine
GB0619822D0 (en) Vaccine
GB0607087D0 (en) Vaccine
GB0619826D0 (en) Vaccine
GB0619820D0 (en) Vaccine
GB0619824D0 (en) Vaccine
GB0620337D0 (en) Vaccine
GB0614254D0 (en) Vaccine
GB0619821D0 (en) Vaccine
GB0620816D0 (en) vaccine
GB0620815D0 (en) Vaccine
GB0606256D0 (en) Anti-atheroma vaccine